Literature DB >> 14675091

Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.

M Ling1, E M Duncan, S E Rodgers, A M Street, J V Lloyd.   

Abstract

In patients with hemophilia A who have an inhibitor to factor (F)VIII measured by Bethesda assay, enzyme-linked immunosorbent assay (ELISA) can also be used to detect the inhibitor. In some studies non-inhibitory antibodies were also detected by ELISA in many patients who were negative by Bethesda assay. Our aim was to investigate whether there is a higher detection rate of FVIII antibodies by ELISA compared with Bethesda assay. We also compared outcomes using three different preparations of recombinant FVIII (rFVIII) to coat the microtiter plates for ELISA. Inhibitor detection by ELISA generally agreed with the Bethesda method. Only four of 26 patients with no clinical suspicion of an inhibitor and with no detectable inhibitor by Bethesda assay showed a non-inhibitory antibody by ELISA, and three of these were only weakly positive. Patients with severe hemophilia A and the intron 22 inversion (n = 21) did not show a higher incidence of non-inhibitory antibodies compared with those without that mutation. Finally, we found that the formulation of rFVIII has a small effect on ELISA performance, mainly in detection of low-level antibody. The results of the present study are in contrast to and fail to confirm previously published reports showing a higher incidence of non-inhibitory antibodies in hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675091     DOI: 10.1046/j.1538-7836.2003.00477.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

2.  Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Authors:  B Boylan; A S Rice; A L Dunn; M D Tarantino; D B Brettler; J C Barrett; C H Miller
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

3.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

4.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 5.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

7.  Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model.

Authors:  Margaret V Ragni; Wenhu Wu; Xiaoyan Liang; Ching-Chuan Hsieh; Andrea Cortese-Hassett; Lina Lu
Journal:  Exp Hematol       Date:  2009-06       Impact factor: 3.084

8.  Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis.

Authors:  A Abdi; M R Bordbar; S Hassan; F R Rosendaal; J G van der Bom; J Voorberg; K Fijnvandraat; S C Gouw
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

9.  Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India.

Authors:  Sachin David; Nitty S Mathews; G Surender Singh; Anu Korula; Fouzia Nambiatheyil Aboobacker; Aby Abraham; Biju George; Alok Srivastava; Vikram Mathews; Sukesh C Nair
Journal:  Blood Coagul Fibrinolysis       Date:  2019-10       Impact factor: 1.276

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.